Literature DB >> 24882622

The oncoprotein HBXIP up-regulates SCG3 through modulating E2F1 and miR-509-3p in hepatoma cells.

Yue Wang1, Ming Cui2, Xiaoli Cai1, Baodi Sun2, Fabao Liu1, Xiaodong Zhang2, Lihong Ye3.   

Abstract

Hepatitis B X-interacting protein (HBXIP) is an important oncoprotein in hepatocarcinogenesis. Here, we found that the expression levels of HBXIP were positively associated with those of Secretogranin III (SCG3) in clinical hepatocellular carcinoma tissues. We identified that HBXIP up-regulated the expression of SCG3 through modulating both E2F transcription factor 1 (E2F1) and miR-509-3p. HBXIP suppressed miR-509-3p through activating NF-κB. In function, we showed that SCG3 increased the proliferation of hepatoma cells and HBXIP enhanced the proliferation of the cells via SCG3 in vitro and in vivo. Thus, we conclude that HBXIP facilitates the proliferation of hepatoma cells through up-regulating SCG3.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  E2F1; HBXIP; Hepatocellular carcinoma; SCG3; miR-509-3p

Mesh:

Substances:

Year:  2014        PMID: 24882622     DOI: 10.1016/j.canlet.2014.05.007

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  13 in total

1.  The LPI/GPR55 axis enhances human breast cancer cell migration via HBXIP and p-MLC signaling.

Authors:  Xiao-Lei Zhou; Xin Guo; Yu-Pin Song; Chong-Yue Zhu; Wei Zou
Journal:  Acta Pharmacol Sin       Date:  2017-11-30       Impact factor: 6.150

2.  Oncoprotein HBXIP induces PKM2 via transcription factor E2F1 to promote cell proliferation in ER-positive breast cancer.

Authors:  Bo-Wen Liu; Tian-Jiao Wang; Lei-Lei Li; Lu Zhang; Yun-Xia Liu; Jin-Yan Feng; Yue Wu; Fei-Fei Xu; Quan-Sheng Zhang; Ming-Zhu Bao; Wei-Ying Zhang; Li-Hong Ye
Journal:  Acta Pharmacol Sin       Date:  2018-06-20       Impact factor: 6.150

Review 3.  Ligandomics: a paradigm shift in biological drug discovery.

Authors:  Wei Li; Iok-Hou Pang; Mario Thiego F Pacheco; Hong Tian
Journal:  Drug Discov Today       Date:  2018-01-08       Impact factor: 7.851

4.  MicroRNA-509-3p inhibits cell proliferation and invasion via downregulation of X-linked inhibitor of apoptosis in glioma.

Authors:  Peng Du; Xinping Luan; Yiwei Liao; Yiti Mu; Yang Yuan; Jingxuan Xu; Jingjing Zhang
Journal:  Oncol Lett       Date:  2017-11-10       Impact factor: 2.967

5.  Functional Genetic Variations at the microRNA Binding-Site in the CD44 Gene Are Associated with Risk of Colorectal Cancer in Chinese Populations.

Authors:  Xiao-Min Wu; Hong-Guo Yang; Bo-An Zheng; Hong-Feng Cao; Zhi-Ming Hu; Wei-Ding Wu
Journal:  PLoS One       Date:  2015-05-26       Impact factor: 3.240

6.  Secretogranin III as a disease-associated ligand for antiangiogenic therapy of diabetic retinopathy.

Authors:  Michelle E LeBlanc; Weiwen Wang; Xiuping Chen; Nora B Caberoy; Feiye Guo; Chen Shen; Yanli Ji; Hong Tian; Hui Wang; Rui Chen; Wei Li
Journal:  J Exp Med       Date:  2017-03-22       Impact factor: 14.307

7.  The oncoprotein HBXIP facilitates metastasis of hepatocellular carcinoma cells by activation of MMP15 expression.

Authors:  Sen Zheng; Huita Wu; Fei Wang; Jie Lv; Jing Lu; Qinliang Fang; Fuqiang Wang; Yuyan Lu; Sheng Zhang; Yaping Xu; Qing Bao; Chengrong Xie; Zhenyu Yin
Journal:  Cancer Manag Res       Date:  2019-05-16       Impact factor: 3.989

Review 8.  RNA N6-methyladenosine modification in solid tumors: new therapeutic frontiers.

Authors:  Laleh Melstrom; Jianjun Chen
Journal:  Cancer Gene Ther       Date:  2020-01-20       Impact factor: 5.987

9.  SCG3 Protein Expression in Glioma Associates With less Malignancy and Favorable Clinical Outcomes.

Authors:  Yi Wang; Nan Ji; Junmei Wang; Jingli Cao; Deling Li; Yang Zhang; Liwei Zhang
Journal:  Pathol Oncol Res       Date:  2021-02-26       Impact factor: 3.201

10.  Oncogenic HBXIP enhances ZEB1 through Sp1 to accelerate breast cancer growth.

Authors:  Yang Jiang; Dan Wang; Hui Ren; Ying Shi; Yufei Gao
Journal:  Thorac Cancer       Date:  2018-10-01       Impact factor: 3.500

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.